Calendario›ASND›TransCon PTH · PaTH Forward

TransCon PTH · PaTH Forward

A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism

Ensayo de Ascendis Pharma A/S en Hipoparatiroidismo · Enfermedades del sistema endocrino · Enfermedades de las paratiroides.

Más ensayos de: Hipoparatiroidismo.

Fase

Fase 2

Estado

Completado

Participantes

59

previstos

Centros

15

Fin del objetivo primario

mar 2020

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en ago 2019.

Qué mide

Eficacia - Criterio de valoracion principal durante el periodo ciego (semana 4)

Cómo lo describe el promotor

En el documentoEn inglés, del registroDuring the first four weeks of the trial, participants were randomly assigned to one of four groups: three groups received fixed doses of TransCon PTH and one group received placebo. TransCon PTH or placebo were administered as a subcutaneous injection using a pre-filled injection pen. Neither trial participants nor their doctors know who has been assigned to each group. After the four weeks, participants continued in the trial as part of a long-term extension period. During the extension, all participants received TransCon PTH, with the dose adjusted to their individual needs. This was a global trial that was conducted in the United States, Canada, Germany, Denmark, Italy and Norway.

Más ensayos de ASND

Todos los de ASND, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT04009291), actualizada en may 2026.